title: Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.
abstract: The pharmacokinetics of cefoperazone 2 g combined with sulbactam 1 g after a single dose administered intravenously were evaluated in 24 subjects with normal and impaired renal function. Subjects were categorized into four groups based on endogenous creatinine clearance Clcr. Patients in groups 1, 2 and 3 had ClcrS of greater than 60, 31 to 60, and 10 to 30 mL/min/1.73 m2, respectively. Patients in group 4 required maintenance haemodialysis and were assumed to have Clcr less than 10 mL/min/1.73 m2. Pharmacokinetic parameters were determined by noncompartmental methods. No significant differences (P greater than 0.05) in mean peak serum cefoperazone-sulbactam concentrations for group 1 (208.4/29.0 mg/L), group 2 (199.0/34.1 mg/L), group 3 (163.2/35.0 mg/L), and group 4 (234.0/66.0 mg/L) were noted. Correlations between both total serum (r = 0.58) and renal (r = 0.35) clearance and creatinine clearances were negative for cefoperazone, although both were shown to decline with diminished renal function. Correlations between serum (r = 0.85) and renal (r = 0.72) clearances and creatinine clearance for sulbactam were, on the other hand, both positive and declined in a linear fashion. No significant differences in steady state volumes of distribution were noted for either cefoperazone (P = 0.53) or sulbactam (P = 0.85) amongst the four groups. After 24 h, urinary recovery was also comparable for both cefoperazone (P = 0.64) and sulbactam (P = 0.85) amongst the four groups. The concentrations of cefoperazone and sulbactam remained at or above the MICs (16/8 mg/L) for common bacterial pathogens for 2.5, 3, 7 and 14 h in groups 1, 2, 3 and 4, respectively.
authors.affiliation: Pharmacy Service, West Los Angeles Medical Center, California 90073.
authors.forename: J P
authors.initials: JP
authors.lastname: Rho
authors.forename: S
authors.initials: S
authors.lastname: Castle
authors.forename: K
authors.initials: K
authors.lastname: Smith
authors.forename: R E
authors.initials: RE
authors.lastname: Bawdon
authors.forename: D C
authors.initials: DC
authors.lastname: Norman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002438:Cefoperazone / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D013407:Sulbactam / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D004338:Drug Combinations; D002438:Cefoperazone; D013407:Sulbactam